Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sabin Strain Inactivated Poliovirus Vaccine · 1 trial · 2 indications
Seroconversion rates of neutralizing antibody against polioviruses of three serotypes, at 28 days after three doses of vaccinationadministered concomitantly with routine vaccines
Incidence of adverse reactions within 7 days after each dose of vaccination Incidence of adverse reactions within 7 days after each dose of vaccination
| Arm | Type | Description |
|---|---|---|
| group C1 | EXPERIMENTAL | Co-administration of sIPV and routine infant vaccines at 6,10,14 weeks old (N=360) |
| group C2 | EXPERIMENTAL | Co-administration of sIPV and routine infant vaccines at 6, 10,14 weeks old |
| group S1 | EXPERIMENTAL | Administration of sIPV at 6,10,14 weeks old; Administration of routine infant vaccines at 8,12,16 weeks old |
| group S2 | EXPERIMENTAL | Administration of routine infant vaccines at 6,10,14 weeks old; Administration of sIPV at 8,12,16 weeks old |
| Name | Type | Description |
|---|---|---|
| Sabin Strain Inactivated Poliovirus Vaccine | BIOLOGICAL | Totally 1440 healthy infants of 6 weeks old (42-47 days) are planned to be enrolled, and then randomized in a 1:1:1:1 ratio into four groups, i.e., co-administration group 1 (group C1), co-administration group 2 (group C2), staggered administration group 1 (group S1) and staggered administration group 2 (group S2). Participants in group C1 and C2 will receive sIPV at 6,10, 14 weeks old, administered concomitantly with routine infant vaccine (may include DTP-HepB-Hib vaccine, PCV10 or rotavirus vaccine in accordance with the local routine vaccination schedule). Participants in group S1 will receive sIPV at 6,10,14 weeks old, and receive routine infant vaccines at 8,12,16 weeks old. Participant s in group S2 will receive routine infant vaccines at 6,10,14 weeks old, and receive sIPV at 8,12, 16 weeks old. |
Inclusion Criteria: 1\) Infants of 6 weeks old (42-47 days); 2) For whom a parent/legal guardian has given written informed consent after the study has been explained; 3) Be able to provide the vaccination records after birth; 4) Negative results in SARS-CoV-2 rapid antigen testing, within 24 hours...
Sabin Strain Inactivated Poliovirus Vaccine, or sIPV, is an investigational vaccine developed by Sinovac Biotech, Ltd for the prevention of poliomyelitis. It is a vaccine candidate designed to protect against polio, a disease caused by poliovirus infection. It is being studied in clinical trials rather than being an approved product.
Sabin Strain Inactivated Poliovirus Vaccine is being developed for the prevention of poliomyelitis, also known as polio. Its intended use is immunization against poliovirus infection. The vaccine is studied in healthy volunteers, including infants from 42 days of age, in countries such as Bangladesh and Pakistan.
Sabin Strain Inactivated Poliovirus Vaccine is being developed by Sinovac Biotech, Ltd, which trades under the ticker SVA. Sinovac is the sponsor of the clinical program for this polio vaccine candidate.
Sabin Strain Inactivated Poliovirus Vaccine has completed a Phase 3 clinical trial. It is an investigational vaccine and is not described as approved. The Phase 3 study, NCT05850364, was a multi-center, open-labelled, randomized, controlled, extended Phase 3 trial that has been completed.
Sabin Strain Inactivated Poliovirus Vaccine has been studied in one clinical trial, NCT05850364, titled a multi-center, open-labelled, randomized, controlled, extended Phase 3 clinical trial of sIPV vaccine. The trial enrolled 1,442 participants, was conducted in Bangladesh and Pakistan, and has been completed.
Yes, Sabin Strain Inactivated Poliovirus Vaccine is also known as sIPV. The abbreviation sIPV appears in the title of its Phase 3 clinical trial, NCT05850364, which evaluated the sIPV vaccine. Readers searching for sIPV are referring to the same Sinovac polio vaccine candidate.